Financial Data and Key Metrics Changes - The company's net revenue for Q3 2021 was $8.8 million, a slight increase of 0.5% from $8.7 million in Q3 2020, driven by a 4.2% increase in home care revenue [7][27] - Gross profit increased by 1.6% to $6.7 million, representing 76.3% of net revenue, compared to 75.4% in the prior year [29] - Net income for the quarter was $224,000 or $0.03 per diluted share, down from $653,000 or $0.07 per diluted share in the prior year [35] Business Line Data and Key Metrics Changes - Home care revenue increased by 4.2% to $8.2 million, attributed to higher referrals and approvals [27] - Institutional revenue decreased by 27.3% to $443,000, primarily due to reduced hospital purchases related to COVID-19 [28] - Home care distributor revenue fell by 36% to $105,000, while international revenue decreased by 44.5% to $76,000 [28] Market Data and Key Metrics Changes - The company experienced a record monthly home care revenue and referrals in March 2021, benefiting from increased patient visits and access for sales representatives as vaccinations became more widespread [8][12] - The institutional segment showed a sequential revenue growth of 43.4%, indicating a recovery trend despite ongoing challenges [11] Company Strategy and Development Direction - The company is focused on expanding its sales force, with plans to hire additional direct sales employees and a regional sales manager [15] - Strategic investments are being made in sales, marketing, infrastructure, market research, and product development to support future revenue growth [14][20] - The institutional strategy aims to strengthen partnerships with integrated delivery networks to augment home care revenues [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about long-term market opportunities for SmartVest, particularly in the context of increasing awareness of bronchiectasis and the benefits of HFCWO therapy [24][67] - The company noted that the extension of the CMS waiver until July 2021 has positively impacted approval rates for home care revenue [10][47] - Management acknowledged challenges in the institutional market due to competition but emphasized the differentiated quality of their products [70] Other Important Information - The company reported a strong balance sheet with cash and cash equivalents of $12.5 million and no long-term debt [36] - Operating expenses increased to $6.5 million, primarily due to higher SG&A expenses related to increased payroll and marketing efforts [30][31] Q&A Session Summary Question: Discussion on distributor strategy and sales organization expansion - Management indicated that the distributor market is still being evaluated for its long-term value and that they will report more on this in the next quarter [40][42] Question: Clarification on market research expenses - Management confirmed that the market research was conducted with a reputable firm to better understand market dynamics and optimize sales rep placement [44][46] Question: Dynamics between Medicare and commercial home care revenue - Management explained the complexities in approval rates between traditional Medicare and commercial plans, noting that access to clinics was limited during the early part of the quarter [48][51] Question: Guidance on R&D and SG&A expenses - Management confirmed that R&D expenses are expected to remain at 4% to 6% of revenue, while SG&A may be slightly elevated due to ongoing strategic investments [52][54] Question: Insights on March's record revenue and future expectations - Management highlighted that March was a strong month, with optimism for continued growth as vaccination rates increase and COVID-19 cases decline [60][63] Question: Competitive landscape and market behavior - Management noted that while competition remains challenging in the institutional market, the home care segment has not seen significant changes in competitive activity [68][70]

[PART I – FINANCIAL INFORMATION](index=4&type=section&id=PART%20I%20%E2%80%93%20FINANCIAL%20INFORMATION) This section details the company's unaudited condensed financial statements, management's analysis, market risk, and internal controls [Item 1. Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) This section presents the unaudited condensed financial statements, including the balance sheets, statements of operations, cash flows, and shareholders' equity, along with detailed notes It provides a snapshot of the company's financial position, performance, and cash movements for the periods ended March 31, 2021, and June 30, 2020 [Condensed Balance Sheets](index=4&type=section&id=Condensed%20Balance%20Sheets) This section presents the company's assets, liabilities, and shareholders' equity as of March 31, 2021, and June 30, 2020 | Metric | March 31, 2021 (Unaudited) | June 30, 2020 | | :------------------------- | :------------------------- | :------------ | | Total Assets | $37,170,563 | $33,244,563 | | Total Liabilities | $4,297,952 | $2,995,248 | | Total Shareholders' Equity | $32,872,611 | $30,249,315 | - Cash increased from **$10.48 million** at June 30, 2020, to **$12.50 million** at March 31, 2021, and accounts receivable (net) increased from **$12.94 million** to **$16.24 million**[10](index=10&type=chunk) [Condensed Statements of Operations](index=5&type=section&id=Condensed%20Statements%20of%20Operations) This section details the company's revenues, gross profit, operating income, and net income for the specified periods | Metric (in thousands) | Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | Nine Months Ended March 31, 2021 | Nine Months Ended March 31, 2020 | | :-------------------- | :-------------------------------- | :-------------------------------- | :------------------------------- | :------------------------------- | | Net Revenues | $8,787 | $8,744 | $26,287 | $25,593 | | Gross Profit | $6,701 | $6,594 | $20,374 | $19,611 | | Operating Income | $243 | $913 | $2,489 | $3,829 | | Net Income | $224 | $653 | $1,962 | $2,853 | | Basic EPS | $0.03 | $0.08 | $0.23 | $0.34 | | Diluted EPS | $0.03 | $0.07 | $0.22 | $0.33 | - Operating expenses for the three months ended March 31, 2021, increased by **13.7%** year-over-year, and for the nine months, increased by **13.3%** year-over-year, driven by higher selling, general and administrative, and research and development costs[12](index=12&type=chunk) [Condensed Statements of Cash Flows](index=6&type=section&id=Condensed%20Statements%20of%20Cash%20Flows) This section outlines the cash flows from operating, investing, and financing activities for the nine months ended March 31, 2021, and 2020 | Metric (in thousands) | Nine Months Ended March 31, 2021 | Nine Months Ended March 31, 2020 | | :------------------------------------ | :------------------------------- | :------------------------------- | | Net Cash Provided by Operating Activities | $2,325 | $2,912 | | Net Cash Used in Investing Activities | $(208) | $(850) | | Net Cash (Used in) Provided by Financing Activities | $(95) | $63 | | Net Increase in Cash | $2,022 | $2,125 | | Cash, End of Period | $12,501 | $9,933 | - The increase in accounts receivable by **$3.30 million** was a significant offset to operating cash flows, primarily due to the 13-month payment cycle for the Medicare portion of the home care business[105](index=105&type=chunk) [Condensed Statements of Shareholders' Equity](index=7&type=section&id=Condensed%20Statements%20of%20Shareholders'%20Equity) This section details changes in shareholders' equity, including retained earnings and additional paid-in capital | Metric | June 30, 2020 | March 31, 2021 | | :------------------------- | :------------ | :------------- | | Total Shareholders' Equity | $30,249,315 | $32,872,611 | | Retained Earnings | $13,683,503 | $15,645,963 | | Additional Paid-in Capital | $16,480,134 | $17,140,274 | - Net income contributed **$223,771** for the three months ended March 31, 2021, and **$1,962,460** for the nine months ended March 31, 2021, to retained earnings[17](index=17&type=chunk) [Notes to Condensed Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Financial%20Statements) This section provides detailed explanations and disclosures supporting the condensed financial statements [Note 1. Interim Financial Reporting](index=9&type=section&id=Note%201.%20Interim%20Financial%20Reporting) This note describes the company's business, product offerings, and the impact of the COVID-19 pandemic - The Company develops, manufactures, and markets innovative airway clearance products applying High Frequency Chest Wall Oscillation (HFCWO) therapy, operating in a single industry segment[21](index=21&type=chunk)[67](index=67&type=chunk)[69](index=69&type=chunk) - International sales were approximately **$297,000** for the nine months ended March 31, 2021, a decrease from **$455,000** in the prior year[21](index=21&type=chunk) - The COVID-19 pandemic's impact on the Company's business remains uncertain, affecting operational and financial performance due to reduced patient consultations and institutional orders[23](index=23&type=chunk)[73](index=73&type=chunk)[75](index=75&type=chunk) [Note 2. Revenues](index=10&type=section&id=Note%202.%20Revenues) This note provides a breakdown of net revenues by market and payer type, along with contract asset details Net Revenues by Market (in thousands) | Market | Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | Nine Months Ended March 31, 2021 | Nine Months Ended March 31, 2020 | | :---------------------- | :-------------------------------- | :-------------------------------- | :------------------------------- | :------------------------------- | | Home Care | $8,163 | $7,834 | $24,529 | $22,995 | | Institutional | $443 | $609 | $1,029 | $1,727 | | Home Care Distributor | $105 | $164 | $432 | $416 | | International | $76 | $137 | $297 | $455 | | **Total Net Revenues** | **$8,787** | **$8,744** | **$26,287** | **$25,593** | Net Home Care Revenue by Payer Type (in thousands) | Payer Type | Nine Months Ended March 31, 2021 | Nine Months Ended March 31, 2020 | | :--------- | :------------------------------- | :------------------------------- | | Commercial | $9,211 | $9,475 | | Medicare | $14,224 | $11,282 | | Medicaid | $669 | $1,432 | | Other | $424 | $806 | | **Total** | **$24,529** | **$22,995** | - Contract assets decreased from **$902,619** at June 30, 2020, to **$557,531** at March 31, 2021, primarily due to reclassification to accounts receivable[51](index=51&type=chunk) [Note 3. Inventories](index=13&type=section&id=Note%203.%20Inventories) This note details the components of inventory, including parts, work in process, finished goods, and obsolescence reserves Inventory Components | Component | March 31, 2021 | June 30, 2020 | | :------------------------- | :------------- | :------------ | | Parts inventory | $1,754,396 | $2,270,766 | | Work in process | $62,033 | $126,726 | | Finished goods | $609,805 | $826,740 | | Estimated inventory to be returned | $129,778 | $150,388 | | Less: Reserve for obsolescence | $(300,000) | $(290,000) | | **Total** | **$2,256,012** | **$3,084,620**| [Note 4. Finite-life Intangible Assets](index=13&type=section&id=Note%204.%20Finite-life%20Intangible%20Assets) This note outlines the activity and balances of finite-life intangible assets, including additions and amortization Finite-life Intangible Assets Activity | Metric | Nine Months Ended March 31, 2021 | Fiscal Year Ended June 30, 2020 | | :--------------------- | :------------------------------- | :------------------------------ | | Balance, beginning | $598,389 | $581,413 | | Additions | $102,826 | $138,739 | | Amortization expense | $(98,785) | $(121,763) | | **Balance, ending** | **$602,430** | **$598,389** | [Note 5. Warranty Liability](index=14&type=section&id=Note%205.%20Warranty%20Liability) This note presents the changes in the warranty reserve, including accruals and expenditures for claims Warranty Liability Changes | Metric | Nine Months Ended March 31, 2021 | Fiscal Year Ended June 30, 2020 | | :-------------------------------------- | :------------------------------- | :------------------------------ | | Warranty reserve, beginning | $740,000 | $810,000 | | Accrual for products sold | $127,500 | $79,000 | | Expenditures and costs incurred for warranty claims | $(127,500) | $(149,000) | | **Warranty reserve, ending** | **$740,000** | **$740,000** | [Note 6. Income Taxes](index=14&type=section&id=Note%206.%20Income%20Taxes) This note details the income tax expense and effective tax rates for the specified periods Income Tax Expense and Effective Tax Rate | Metric | Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | Nine Months Ended March 31, 2021 | Nine Months Ended March 31, 2020 | | :---------------------- | :-------------------------------- | :-------------------------------- | :------------------------------- | :------------------------------- | | Income Tax Expense | $29,000 | $294,000 | $555,000 | $1,087,000 | | Effective Tax Rate | 11.5% | 31.0% | 22.0% | 27.6% | - The effective tax rate for the three months ended March 31, 2021, decreased by **14.6%** due to a **$37,000** discrete tax benefit from lower federal and state tax estimates[57](index=57&type=chunk) [Note 7. Financing Arrangements](index=14&type=section&id=Note%207.%20Financing%20Arrangements) This note describes the company's revolving line of credit and associated covenants - The Company renewed its **$2.5 million** revolving line of credit on December 18, 2020, with no outstanding principal balance as of March 31, 2021[59](index=59&type=chunk) - The credit facility is secured by substantially all tangible and intangible assets and includes covenants such as a minimum tangible net worth of not less than **$10,125,000**[60](index=60&type=chunk) [Note 8. Share-Based Compensation](index=15&type=section&id=Note%208.%20Share-Based%20Compensation) This note provides details on stock option transactions and share-based compensation expense Stock Option Transactions (Nine Months Ended March 31, 2021) | Metric | Number of Shares | Weighted Average Exercise Price per Share | | :---------------------- | :--------------- | :---------------------------------------- | | Outstanding at June 30, 2020 | 590,780 | $4.34 | | Granted | 61,017 | $14.14 | | Exercised | (71,150) | $5.09 | | Cancelled or Forfeited | (109,198) | $6.24 | | **Outstanding at March 31, 2021** | **471,449** | **$5.05** | - Share-based compensation expense increased to approximately **$756,000** for the nine months ended March 31, 2021, from **$677,000** in the prior year[62](index=62&type=chunk) - As of March 31, 2021, there were **71,255 shares** of unvested restricted stock with a weighted average fair value of **$10.80 per share**[64](index=64&type=chunk) [Note 9. Commitments and Contingencies](index=15&type=section&id=Note%209.%20Commitments%20and%20Contingencies) This note addresses the company's involvement in legal claims and potential litigation - The Company is occasionally involved in claims and disputes in the ordinary course of business but is not aware of any undisclosed actual or threatened litigation that would have a material adverse effect on its financial condition or results of operations[65](index=65&type=chunk)[125](index=125&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=15&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section provides an overview of Electromed's business, critical accounting policies, and a detailed analysis of its financial performance and condition for the periods presented It highlights the impacts of the COVID-19 pandemic, revenue trends across different markets, changes in operating expenses, and the company's liquidity and capital resources [Overview](index=15&type=section&id=Overview) This section introduces Electromed's core business, products, and reimbursement landscape - Electromed, Inc. develops and provides innovative airway clearance products, including the SmartVest® Airway Clearance System, utilizing High Frequency Chest Wall Oscillation (HFCWO) technologies for patients of all ages[67](index=67&type=chunk)[69](index=69&type=chunk) - The SmartVest System is often eligible for reimbursement from major private insurance providers, HMOs, state Medicaid systems, and the federal Medicare system, which is an important consideration for patients[70](index=70&type=chunk) [Critical Accounting Policies and Estimates](index=16&type=section&id=Critical%20Accounting%20Policies%20and%20Estimates) This section identifies key accounting policies requiring significant management judgment and estimation - Critical accounting policies requiring significant judgment include revenue recognition and the estimation of variable consideration, allowance for doubtful accounts, inventory obsolescence, share-based compensation, and warranty liability[72](index=72&type=chunk) [Impacts of COVID-19 on Our Business and Operations](index=16&type=section&id=Impacts%20of%20COVID-19%20on%20Our%20Business%20and%20Operations) This section discusses the pandemic's effects on the company's operations, patient access, and revenue trends - The COVID-19 pandemic has negatively impacted business, leading to restricted access to healthcare facilities, reduced patient consultations, and postponed institutional orders, affecting operating results and cash flows[75](index=75&type=chunk) - Home care referrals and approvals increased significantly in March 2021, benefiting from increased patient visits, greater sales team access, and the CMS waiver for respiratory-related products[75](index=75&type=chunk)[81](index=81&type=chunk) - Institutional revenue has been negatively impacted since the onset of the COVID-19 pandemic due to hospitals and long-term care facilities adjusting operating protocols and procurement management[76](index=76&type=chunk) [Results of Operations](index=18&type=section&id=Results%20of%20Operations) This section analyzes the company's financial performance, including revenue, gross profit, and operating expenses - Net income decreased by **65.8%** for the three months and **31.1%** for the nine months ended March 31, 2021, primarily due to increased strategic investments in SG&A and R&D, partially offset by stronger home care revenue and higher gross margin percentage[104](index=104&type=chunk) - Gross profit percentage increased to **76.3%** (three months) and **77.5%** (nine months) due to a higher mix of home care revenue and a favorable mix of Medicare within the home care channel[90](index=90&type=chunk) [Net Revenues](index=18&type=section&id=Net%20Revenues) This section analyzes revenue trends across home care, institutional, distributor, and international markets Net Revenues (in thousands) | Market | Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | Nine Months Ended March 31, 2021 | Nine Months Ended March 31, 2020 | | :---------------------- | :-------------------------------- | :-------------------------------- | :------------------------------- | :------------------------------- | | Home care | $8,163 | $7,834 | $24,529 | $22,995 | | Institutional | $443 | $609 | $1,029 | $1,727 | | Home care distributor | $105 | $164 | $432 | $416 | | International | $76 | $137 | $297 | $455 | | **Total** | **$8,787** | **$8,744** | **$26,287** | **$25,593** | - Home care revenue increased by **4.2%** for the three months and **6.7%** for the nine months ended March 31, 2021, driven by increased referrals and approvals, a hybrid selling model, and the CMS waiver[85](index=85&type=chunk) - Institutional revenue decreased by **27.3%** for the three months and **40.4%** for the nine months ended March 31, 2021, primarily due to the continued impact of COVID-19 on hospital purchasing activity[87](index=87&type=chunk) [Gross profit](index=18&type=section&id=Gross%20profit) This section examines the gross profit and gross margin percentage, highlighting factors influencing changes Gross Profit (in thousands) | Metric | Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | Nine Months Ended March 31, 2021 | Nine Months Ended March 31, 2020 | | :----------- | :-------------------------------- | :-------------------------------- | :------------------------------- | :------------------------------- | | Gross Profit | $6,701 | $6,594 | $20,374 | $19,611 | | % of Revenue | 76.3% | 75.4% | 77.5% | 76.6% | - The increase in gross profit percentage was primarily due to a higher mix of home care revenue and a favorable mix of Medicare within the home care channel[90](index=90&type=chunk) [Operating expenses](index=19&type=section&id=Operating%20expenses) This section details changes in selling, general and administrative, and research and development expenses Operating Expenses (in thousands) | Metric | Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | Nine Months Ended March 31, 2021 | Nine Months Ended March 31, 2020 | | :-------------------------------- | :-------------------------------- | :-------------------------------- | :------------------------------- | :------------------------------- | | Selling, General and Administrative | $6,051 | $5,288 | $16,490 | $15,148 | | Research and Development | $407 | $392 | $1,396 | $634 | | **Total Operating Expenses** | **$6,458** | **$5,680** | **$17,886** | **$15,783** | - Selling, general and administrative (SG&A) expenses increased by **14.4%** (three months) and **8.9%** (nine months) due to a higher average number of sales and marketing personnel, increased temporary resources for systems infrastructure investments, and a direct-to-consumer marketing campaign[93](index=93&type=chunk)[94](index=94&type=chunk)[96](index=96&type=chunk) - Research and development (R&D) expenses increased by **3.8%** (three months) and **120.2%** (nine months), primarily due to next-generation platform development activities[98](index=98&type=chunk) [Interest income, net](index=19&type=section&id=Interest%20income,%20net) This section discusses the company's net interest income and the factors contributing to its changes Net Interest Income (in thousands) | Metric | Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | Nine Months Ended March 31, 2021 | Nine Months Ended March 31, 2020 | | :----------------- | :-------------------------------- | :-------------------------------- | :------------------------------- | :------------------------------- | | Interest Income, Net | $10 | $34 | $29 | $111 | - The decrease in net interest income was primarily due to lower rates earned on cash deposits[99](index=99&type=chunk) [Income tax expense](index=19&type=section&id=Income%20tax%20expense) This section analyzes the income tax expense and effective tax rates, including discrete tax benefits Income Tax Expense and Effective Tax Rate | Metric | Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | Nine Months Ended March 31, 2021 | Nine Months Ended March 31, 2020 | | :---------------------- | :-------------------------------- | :-------------------------------- | :------------------------------- | :------------------------------- | | Income Tax Expense | $29,000 | $294,000 | $555,000 | $1,087,000 | | Effective Tax Rate | 11.5% | 31.0% | 22.0% | 27.6% | - Estimated income tax expense for the nine months ended March 31, 2021, included a **$37,000** discrete tax benefit from lower federal and state taxes and a **$32,000** discrete tax benefit related to stock option exercises, decreasing the effective tax rates[101](index=101&type=chunk) [Net income](index=20&type=section&id=Net%20income) This section reviews the company's net income and the primary drivers of its changes Net Income (in thousands) | Metric | Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | Nine Months Ended March 31, 2021 | Nine Months Ended March 31, 2020 | | :--------- | :-------------------------------- | :-------------------------------- | :------------------------------- | :------------------------------- | | Net Income | $224 | $653 | $1,962 | $2,853 | - The decrease in net income was driven by increased strategic investments in selling, general and administrative (SG&A) and research and development (R&D), partially offset by stronger home care revenue performance and a higher gross margin percentage[104](index=104&type=chunk) [Liquidity and Capital Resources](index=20&type=section&id=Liquidity%20and%20Capital%20Resources) This section assesses the company's cash flows, working capital, and ability to meet its financial obligations - The Company believes its working capital of approximately **$28.05 million** and available borrowings under its existing credit facility will provide adequate liquidity during fiscal 2021[108](index=108&type=chunk) - The **$2.5 million** revolving line of credit was renewed on December 18, 2020, with no outstanding principal balance as of March 31, 2021[109](index=109&type=chunk) [Cash Flows from Operating Activities](index=20&type=section&id=Cash%20Flows%20from%20Operating%20Activities) This section details the sources and uses of cash from the company's primary business operations Net Cash Provided by Operating Activities (in thousands) | Metric | Nine Months Ended March 31, 2021 | | :-------------------------------------- | :------------------------------- | | Net income | $1,962 | | Increase in accounts payable and accrued liabilities | $1,219 | | Decrease in contract assets | $345 | | Decrease in inventory | $839 | | Increase in accounts receivable | $(3,296) | | **Net cash provided by operating activities** | **$2,325** | - The increase in accounts receivable was primarily due to an increase in the Medicare portion of the home care business, which has a 13-month payment cycle[105](index=105&type=chunk) [Cash Flows from Investing Activities](index=20&type=section&id=Cash%20Flows%20from%20Investing%20Activities) This section outlines cash flows related to the acquisition and disposal of long-term assets Cash Used in Investing Activities (in thousands) | Metric | Nine Months Ended March 31, 2021 | | :-------------------------------------- | :------------------------------- | | Expenditures for property and equipment | $(105) | | Expenditures for finite-life intangible assets | $(103) | | **Net cash used in investing activities** | **$(208)** | [Cash Flows from Financing Activities](index=20&type=section&id=Cash%20Flows%20from%20Financing%20Activities) This section describes cash flows from debt and equity transactions Cash Flows from Financing Activities (in thousands) | Metric | Nine Months Ended March 31, 2021 | | :-------------------------------------- | :------------------------------- | | Issuance of common stock upon exercise of options | $46 | | Taxes paid on net share settlement of stock option exercises | $(141) | | **Net cash (used in) provided by financing activities** | **$(95)** | [Adequacy of Capital Resources](index=20&type=section&id=Adequacy%20of%20Capital%20Resources) This section evaluates the sufficiency of the company's working capital and credit facilities for future operations - The Company's working capital of approximately **$28.05 million** and available borrowings under its credit facility are deemed adequate for fiscal 2021[108](index=108&type=chunk) - The credit facility contains financial and nonfinancial covenants, including a minimum tangible net worth of not less than **$10,125,000** and restrictions on incurring additional indebtedness or paying dividends[110](index=110&type=chunk) [Off-Balance Sheet Arrangements](index=21&type=section&id=Off-Balance%20Sheet%20Arrangements) This section discloses any off-balance sheet arrangements impacting the company's financial position - As of March 31, 2021, the Company had no off-balance sheet arrangements[114](index=114&type=chunk) [Cautionary Note Regarding Forward-Looking Statements](index=21&type=section&id=Cautionary%20Note%20Regarding%20Forward-Looking%20Statements) This section warns about inherent risks and uncertainties associated with forward-looking statements in the report - The report contains forward-looking statements subject to risks and uncertainties, including the duration and severity of the COVID-19 pandemic, competitive market, changes to Medicare, Medicaid, or private insurance reimbursement policies, and state and federal health care laws[115](index=115&type=chunk)[116](index=116&type=chunk) - Other risk factors include the Company's ability to develop new sales channels, maintain regulatory compliance, protect and expand its intellectual property portfolio, and risks associated with international market expansion and planned sales force expansion[116](index=116&type=chunk)[118](index=118&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=22&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, Electromed, Inc. is not required to provide disclosures regarding quantitative and qualitative market risk - The Company is exempt from providing market risk disclosures as it is a smaller reporting company[120](index=120&type=chunk) [Item 4. Controls and Procedures](index=22&type=section&id=Item%204.%20Controls%20and%20Procedures) The principal executive and financial officers concluded that the Company's disclosure controls and procedures were effective as of March 31, 2021, ensuring timely and accurate reporting There were no material changes to internal control over financial reporting during the quarter - The principal executive officer and principal financial officer concluded that the Company's disclosure controls and procedures were effective as of March 31, 2021[122](index=122&type=chunk) - There were no material changes in the Company's internal control over financial reporting during the quarter ended March 31, 2021[123](index=123&type=chunk) [PART II – OTHER INFORMATION](index=22&type=section&id=PART%20II%20%E2%80%93%20OTHER%20INFORMATION) This section covers legal proceedings, risk factors, equity sales, defaults, safety disclosures, and other miscellaneous information [Item 1. Legal Proceedings](index=22&type=section&id=Item%201.%20Legal%20Proceedings) The Company is occasionally involved in legal actions in the ordinary course of business but is not aware of any undisclosed litigation that would materially adversely affect its financial condition or results of operations - The Company is not aware of any undisclosed actual or threatened litigation that would have a material adverse effect on its financial condition or results of operations[125](index=125&type=chunk) [Item 1A. Risk Factors](index=22&type=section&id=Item%201A.%20Risk%20Factors) As a smaller reporting company, Electromed, Inc. is not required to provide disclosures regarding risk factors in this section - The Company is exempt from providing risk factor disclosures as it is a smaller reporting company[126](index=126&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=22&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) There were no unregistered sales of equity securities or use of proceeds to report for the period - No unregistered sales of equity securities or use of proceeds were reported[128](index=128&type=chunk) [Item 3. Defaults Upon Senior Securities](index=23&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) There were no defaults upon senior securities to report for the period - No defaults upon senior securities were reported[131](index=131&type=chunk) [Item 4. Mine Safety Disclosures](index=23&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) There were no mine safety disclosures to report for the period - No mine safety disclosures were reported[133](index=133&type=chunk) [Item 5. Other Information](index=23&type=section&id=Item%205.%20Other%20Information) There was no other information to report for the period - No other information was reported[135](index=135&type=chunk) [Item 6. Exhibits](index=23&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including corporate organizational documents, certifications under the Sarbanes-Oxley Act, and XBRL financial statements - Exhibits include Composite Articles of Incorporation, Amended and Restated Bylaws, Certifications Pursuant to Section 302 and 906 of the Sarbanes-Oxley Act, and XBRL financial statements[137](index=137&type=chunk)

Electromed, Inc. (NYSE:ELMD) Q2 2021 Earnings Conference Call February 9, 2021 5:00 PM ET Company Participants Devin Sullivan - IR Kathleen Skarvan - CEO, President & Director Michael MacCourt - CFO, Treasurer & Secretary Conference Call Participants Kyle Bauser - Colliers Securities James Terwilliger - Northland Capital Markets Operator Greetings, and welcome to the Electromed Second Quarter Fiscal 2021 Financial Results Conference Call. [Operator Instructions]. As a reminder, this conference is being reco ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File No.: 001-34839 Electromed, Inc. (Exact Name of Registrant as Specified in its Charter) | --- | --- | --- | |------------ ...

Financial Data and Key Metrics Changes - In Q1 fiscal 2021, overall net revenue was $8 million, a decrease of 3.6% compared to the same period last year [7][21] - Net income was approximately $535,000, or $0.06 per diluted share, down from $1 million, or $0.12 per diluted share in the prior year [13][29] - Gross profit dollars decreased by 3.1% to $6.1 million, representing 76.8% of net revenue [24] Business Line Data and Key Metrics Changes - Home care revenue was approximately $7.5 million, remaining flat year-over-year, but increased by 17.9% compared to the previous quarter [21] - Institutional revenue decreased by 55.5% year-over-year to $278,000 due to reduced hospital purchases related to COVID-19 [22] - Distributor revenue increased by 48.3% to $178,000 from $120,000 in the first quarter of fiscal 2020 [23] Market Data and Key Metrics Changes - International revenue totaled $84,000, up from $66,000 in the prior year period, although it is not a strategic growth area for the company [23] - The home care business benefited from the CMS waiver, which has been extended, aiding revenue growth [9] Company Strategy and Development Direction - The company aims to strengthen its institutional strategy by fortifying hospital call points and partnerships with integrated delivery networks [11] - There is a focus on expanding the sales organization and investing in direct-to-consumer marketing to increase awareness of bronchiectasis and SmartVest [14][54] - The long-term growth thesis remains intact, targeting a significant market opportunity in non-cystic fibrosis bronchiectasis [18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about resuming long-term low double-digit revenue growth as the impact of COVID-19 abates [19] - The company remains committed to maintaining profitability and has not experienced significant disruptions in manufacturing or supply chain [15][30] Other Important Information - The company appointed Kristine Owata as Vice President of Reimbursement and Payer Relations, bringing 15 years of experience [16][17] - R&D expenses increased significantly to $481,000, primarily for next-generation product development [27] Q&A Session Summary Question: Will the CMS waiver be extended beyond January? - Management indicated there is a good chance the waiver may be extended based on COVID-19 case trends [32][33] Question: What are the plans for capital allocation? - Management stated that all options, including acquisitions and dividends, are on the table, but priority will be given to strategies for accelerating growth [34][36] Question: What is the status of the multicenter study? - The study is underway with enrollment ongoing, and it aims to include quality of life surveys, which are recognized by the FDA as important outcomes [38][40] Question: How will R&D spending be managed going forward? - R&D spending is expected to remain at similar levels for the duration of fiscal 2021 [45] Question: What is the outlook for SG&A expenses? - Management plans to expand the sales organization and invest in infrastructure to support future growth [54]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File No.: 001-34839 Electromed, Inc. (Exact Name of Registrant as Specified in its Charter) | --- | --- | --- | |----------- ...

Electromed, Inc. (NYSE:ELMD) Q4 2020 Results Earnings Conference Call August 25, 2020 5:00 PM ET Company Participants Kalle Ahl - IR, The Equity Group Inc. Kathleen Skarvan - President and Chief Executive Officer Mike MacCourt - Chief Financial Officer Conference Call Participants Kyle Bauser - Colliers Securities Operator Greetings and welcome to Electromed Inc.'s Fourth Quarter and Full Year Fiscal 2020 Financial Results Conference Call. At this time all participants are in a listen-only mode. A question- ...

Revenue Performance - Revenue for the fiscal year ended June 30, 2020, is summarized in thousands of dollars, indicating a comparison with the previous fiscal year[142]. - Total revenue for fiscal 2020 was approximately $32,471,000, an increase of 3.7% compared to $31,300,000 in fiscal 2019[143]. - Home care revenue increased by 1.3%, or approximately $374,000, for fiscal 2020, driven by a higher percentage of approved referrals[143]. - Institutional revenue rose by 24.7%, or approximately $396,000, in fiscal 2020, primarily due to higher selling prices and an increase in the number of devices sold[144]. Profitability and Expenses - Gross profit for fiscal 2020 was approximately $25,200,000, representing 77.6% of net revenues, up from 76.2% in fiscal 2019[148]. - Selling, general and administrative expenses decreased by approximately $490,000, or 2.4%, to approximately $19,945,000 in fiscal 2020[150]. - Research and development expenses were approximately $1,050,000, or 3.2% of net revenues, for fiscal 2020, with expectations for a slight increase in spending for fiscal 2021[156]. - Net income for fiscal 2020 was approximately $4,161,000, compared to $1,980,000 in fiscal 2019, driven by increased gross profit and government stimulus income[163]. Government Assistance and Impact of COVID-19 - The company received a stimulus payment of approximately $913,000 under the CARES Act to offset revenue losses due to the COVID-19 pandemic[129]. - The COVID-19 pandemic has negatively impacted institutional revenue as hospitals adjusted their operating protocols, affecting procurement management[123]. - The company initiated cost-containment measures in response to the COVID-19 pandemic, including reducing discretionary spending and employee furloughs[126]. - The company recorded $913,000 of government stimulus income related to the COVID-19 pandemic in fiscal 2020[158]. Product Information and Market Strategy - The SmartVest SQL product has been sold in the domestic home care market since 2014, with enhancements in programmability and ease of use compared to the previous model[116]. - The company employs a direct-to-patient and provider model, allowing it to capture both manufacturer and distributor margins[118]. - The SmartVest System is often eligible for reimbursement from major private insurance providers, which is crucial for patient access to therapy[117]. - The company aims to expand its clinical evidence base to increase utilization of the SmartVest for patients with bronchiectasis[119]. - Key growth strategies for fiscal 2021 include increasing referrals in adult pulmonology/bronchiectasis and enhancing patient and provider support[119]. Financial Metrics and Adjustments - Cash flows from operating activities for fiscal 2020 were approximately $4,196,000, consisting of net income and non-cash expenses[164]. - The effective tax rate for fiscal 2020 was 20.6%, down from 32.3% in fiscal 2019, influenced by various tax credits and deductions[162]. - Net revenues for the twelve months ended June 30, 2019, were reported at $31,299,750, with no adjustments made[176]. - Gross profit for the same period was $23,847,944, indicating a strong revenue generation capability[176]. - Operating income adjusted to $2,829,623 after accounting for the adoption of ASC 842, reflecting an increase of $11,112[176]. - The net income for the twelve months ended June 30, 2019, was reported at $1,980,330, after adjustments[176]. - Basic earnings per share remained at $0.24, with diluted earnings per share also unchanged at $0.23[176]. - Total operating expenses were adjusted to $21,018,321, with selling, general, and administrative expenses slightly reduced to $20,435,010[176].

Financial Data and Key Metrics Changes - The company reported a net revenue increase of 18% to $8.7 million in Q3 2020 from $7.4 million in Q3 2019, driven by growth in home care revenue [18] - Net income for the third quarter was approximately $653,000, or $0.07 per diluted share, compared to $353,000, or $0.04 per diluted share in the prior year [24] - Operating income increased to $913,000 in Q3 2020 from $465,000 in the same period of the prior year [23] Business Line Data and Key Metrics Changes - Home care revenue increased by 14.3% to $7.8 million, primarily due to a higher average selling price per device and a greater percentage of referrals getting approved [18] - Institutional revenue surged by 46.9% to $609,000 from $414,000 in the prior year, driven by higher average selling prices and increased volume [18] - The company began selling into home medical equipment distributors, generating $165,000 in revenue during Q3 2020 [18] Market Data and Key Metrics Changes - International revenue, which is not a strategic growth area, totaled approximately $137,000 compared to $142,000 in the prior year [19] - The company noted that many clinics temporarily closed or restricted their operating hours due to COVID-19, impacting the home care referral pipeline [9] Company Strategy and Development Direction - The company aims for long-term double-digit revenue growth once the impact of COVID-19 subsides, emphasizing its essential business status and strong balance sheet [12] - The management highlighted the significant market opportunity in non-cystic fibrosis bronchiectasis, estimated at over 4 million individuals in the U.S. [16] - The company is focusing on building awareness of recent CMS waivers that modify rules for prescribing respiratory-related devices, which could enhance patient access [8] Management's Comments on Operating Environment and Future Outlook - Management expressed uncertainty regarding the long-term impact of COVID-19 on business and financial performance but remains confident in the company's ability to weather the storm [11] - The company has implemented cost-saving measures, expecting approximately $450,000 in savings per quarter due to reduced discretionary spending [11] - Management is optimistic about returning to a strong cadence of profitable growth as the nation emerges from the COVID-19 crisis [16] Other Important Information - The company reported cash of $9.9 million, no debt, and working capital of $24.2 million as of March 31, 2020 [25] - A stimulus payment of $913,000 related to the CARES Act was received post-quarter end, which may help offset revenue losses due to COVID-19 [26] Q&A Session Summary Question: How is the relaxed CMS guidelines impacting the business? - Management indicated that the waiver primarily assists patients in the home care environment, particularly for those discharged from hospitals [29] Question: Have there been any changes in the conditions for which SmartVest is being prescribed? - Management noted an increase in prescriptions for COPD and COVID-19 patients, which were not typically qualified before [30] Question: What percentage of active accounts have reopened? - Management reported a gradual increase in the number of clinics reopening and conducting face-to-face visits, with a high single-digit percentage shift observed [32]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File No.: 001-34839 Electromed, Inc. (Exact Name of Registrant as Specified in its Charter) Minnesota 41-1732920 (State or other ...